Zurcher Kantonalbank (Zurich Cantonalbank) Cure Vac N.V. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$33.8 Billion
Q1 2025

A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Cure Vac N.V. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 29,125 shares of CVAC stock, worth $134,848. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,125

Previous 25,477 14.32%

Holding current value

$134,848

Previous $86,000 6.98%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 07, 2025	BUY	$2.77 - $4.68 $10,104 - $17,072	3,648 Added 14.32%	29,125 $80,000
Q2 2024 Jul 29, 2024	BUY	$2.31 - $4.99 $2 - $4	1 Added 0.0%	25,477 $86,000
Q2 2023 Aug 07, 2023	BUY	$6.69 - $12.25 $60,598 - $110,960	9,058 Added 55.17%	25,476 $265,000
Q1 2023 May 08, 2023	SELL	$6.38 - $12.5 $6,533 - $12,800	-1,024 Reduced 5.87%	16,418 $114,000
Q4 2022 Feb 01, 2023	BUY	$5.75 - $8.5 $51,870 - $76,678	9,021 Added 107.13%	17,442 $105,000
Q3 2022 Nov 09, 2022	SELL	$7.48 - $15.24 $173,319 - $353,126	-23,171 Reduced 73.34%	8,421 $66,000
Q2 2022 Aug 09, 2022	BUY	$13.18 - $19.41 $138,851 - $204,484	10,535 Added 50.03%	31,592 $430,000
Q1 2022 Apr 21, 2022	BUY	$14.73 - $35.25 $69,820 - $167,085	4,740 Added 29.05%	21,057 $413,000
Q4 2021 Feb 01, 2022	BUY	$33.72 - $48.22 $221,810 - $317,191	6,578 Added 67.54%	16,317 $560,000
Q3 2021 Nov 15, 2021	BUY	$49.26 - $74.5 $277,235 - $419,286	5,628 Added 136.9%	9,739 $532,000
Q2 2021 Jul 30, 2021	BUY	$56.91 - $127.53 $233,957 - $524,275	4,111 New	4,111 $302,000

Others Institutions Holding CVAC

# of Institutions

Shares Held

10.7M

Call Options Held

75.1K

Put Options Held

86.7K

View Full List

About CureVac N.V.

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $868M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

More about CVAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account

Zurcher Kantonalbank (Zurich Cantonalbank) Cure Vac N.V. Transaction History